{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Griese M"],"funding":["E-Rare","FP7","Deutsches Zentrum für Lungenforschung"],"pagination":["289"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9308121"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["17(1)"],"pubmed_abstract":["Background
No results of controlled trials are available for any of the few treatments offered to children with interstitial lung diseases (chILD). We evaluated hydroxychloroquine (HCQ) in a phase 2, prospective, multicentre, 1:1-randomized, double-blind, placebo-controlled, parallel-group/crossover trial. HCQ (START arm) or placebo were given for 4 weeks. Then all subjects received HCQ for another 4 weeks. In the STOP arm subjects already taking HCQ were randomized to 12 weeks of HCQ or placebo (= withdrawal of HCQ). Then all subjects stopped treatment and were observed for another 12 weeks.Results
26 subjects were included in the START arm, 9 in the STOP arm, of these four subjects participated in both arms. The primary endpoint, presence or absence of a response to treat"],"journal":["Orphanet journal of rare diseases"],"pubmed_title":["Randomized controlled phase 2 trial of hydroxychloroquine in childhood interstitial lung disease."],"pmcid":["PMC9308121"],"funding_grant_id":["82DZLG13A2","No. 305653","01GM1702"],"pubmed_authors":["Ruckes C","Feilcke M","Prenzel F","Olivier M","Kappler M","Griese M","Seidl E","Carlens J","Neuner D","Hebestreit H","Baden W","Stichtenoth G","Ahrens F","Stohr L","Eismann C","Hengst M","Sebah D","Stahl M","HCQ-study group","Stauffer G","Rietschel C","Brinkmann F","Schulze J","Gebhardt J","Vieweg L","Nahrlich L","Zielen S","Stock P","Koerner-Rettberg C","Nickolay T","Lau SG","Gorbulev S","Wetzke M","Schwerk N","Segerer F","Kitz R","Philipp U","Kronfeld K","Rock H","Witt S","Anne S","Bagheri-Potthof A","Thalmeier A","Sommerburg O","Strenge-Hesse A","Stehling F","Babl J","Mehl A","Thome U","Anthony G","Kopp M"],"additional_accession":[]},"is_claimable":false,"name":"Randomized controlled phase 2 trial of hydroxychloroquine in childhood interstitial lung disease.","description":"Background
No results of controlled trials are available for any of the few treatments offered to children with interstitial lung diseases (chILD). We evaluated hydroxychloroquine (HCQ) in a phase 2, prospective, multicentre, 1:1-randomized, double-blind, placebo-controlled, parallel-group/crossover trial. HCQ (START arm) or placebo were given for 4 weeks. Then all subjects received HCQ for another 4 weeks. In the STOP arm subjects already taking HCQ were randomized to 12 weeks of HCQ or placebo (= withdrawal of HCQ). Then all subjects stopped treatment and were observed for another 12 weeks.Results
26 subjects were included in the START arm, 9 in the STOP arm, of these four subjects participated in both arms. The primary endpoint, presence or absence of a response to treat","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Jul","modification":"2025-04-25T18:12:06.867Z","creation":"2022-08-06T22:39:41.659Z"},"accession":"S-EPMC9308121","cross_references":{"pubmed":["35871071"],"doi":["10.1186/s13023-022-02399-2"]}}